The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Charles River Laboratories International Inc

NYSE: CRL
Last

(U.S.) $100.92

Today's change+0.29 +0.29%
Updated June 27 11:53 AM EDT. Delayed by at least 15 minutes.
 

Charles River Laboratories International Inc

NYSE: CRL
Last

(U.S.) $100.92

Today's change+0.29 +0.29%
Updated June 27 11:53 AM EDT. Delayed by at least 15 minutes.

Charles River Laboratories International Inc up (U.S.)$0.29

Charles River Laboratories International Inc is up today by (U.S.)$0.29 or 0.29% to (U.S.)$100.92. Over the last five days, shares have gained 1.84% and 32.46% year to date. Shares have outperformed the S&P 500 by 11.01% during the last year.

Key company metrics

  • Open(U.S.) $100.64
  • Previous close(U.S.) $100.63
  • High(U.S.) $101.21
  • Low(U.S.) $99.59
  • Bid / Ask(U.S.) $100.93 / (U.S.) $101.05
  • YTD % change+32.46%
  • Volume40,874
  • Average volume (10-day)371,510
  • Average volume (1-month)315,240
  • Average volume (3-month)365,602
  • 52-week range(U.S.) $67.20 to (U.S.) $101.23
  • Beta1.04
  • Trailing P/E29.64×
  • P/E 1 year forward19.74×
  • Forward PEG1.76×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $3.40
Updated June 27 11:53 AM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+9.34%

Based on its net profit margin of 9.34%, Charles River Laboratories International Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.01%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2017Q4/2016Q3/2016Q2/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedApr 01, 201704/01/2017Dec 31, 201612/31/2016Sep 24, 201609/24/2016Jun 25, 201606/25/2016
Revenue446467426434
Total other revenue--------
Total revenue446467426434
Gross profit172180156170
Total cost of revenue274287269264
Total operating expense376398367376
Selling / general / administrative91948391
Research & development--------
Depreciation / amortization11121211
Interest expense (income), net operating--------
Unusual expense (income)1439
Other operating expenses, total--------
Operating income69695958
Interest income (expense), net non-operating-7-8-7-9
Gain (loss) on sale of assets--------
Other--------
Income before tax78645354
Income after tax47453836
Income tax, total31181619
Net income47453835
Total adjustments to net income--------
Net income before extra. items47453735
Minority interest0-100
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items47453735
Inc. avail. to common incl. extra. items47453835
Diluted net income47453835
Dilution adjustment--------
Diluted weighted average shares48484848
Diluted EPS excluding extraordinary itemsvalue per share0.970.930.780.73
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share0.991.060.940.86